

intensivists who, throughout these 25 years, have developed their cardiac pacing activity and collaborated developing the registry.

References

1. Guía de formación de especialistas en Medicina intensiva. Ministerio de Consumo y Bienestar Social. [Accessed 16 September 2019]. Available from: https://www.mscbs.gob.es/profesionales/formacion/docs/Medicina_Intensiva.pdf.
2. García Urrea F, Porres Aracama JM, Choperena Alzugaray G, Luque Lezcano O, Marco Garde P, Grupo de Trabajo de Cuidados Intensivos Cardiológicos SEMICYUC. La implantación de marcapasos definitivos en los Servicios de Medicina intensiva durante el año 1994. *Med Intensiva*. 1996;20:305–12.
3. Pombo Jiménez M, Cano Pérez O, Lorente Carreño D, Chimen García J. Registro Español de Marcapasos. XV Informe Oficial de la Sección de Estimulación Cardíaca de la Sociedad Española de Cardiología (2017). *Rev Esp Cardiol*. 2018;71:1059–68, <http://dx.doi.org/10.1016/j.recesp.2018.07.029>.
4. Porres Aracama JM. Pacientes críticos portadores de marcapasos y desfibriladores automáticos. *Med Intensiva*. 2006;30:280–3, [http://dx.doi.org/10.1016/S0210-5691\(06\)74525-9](http://dx.doi.org/10.1016/S0210-5691(06)74525-9).
5. Zubia Olaskoaga F, García Urrea F. Informe del registro MAMI (base de datos de marcapasos definitivos en Medicina Intensiva) 1996–2003. *Med Intensiva*. 2005;29:265–71, [http://dx.doi.org/10.1016/S0210-5691\(05\)74243-1](http://dx.doi.org/10.1016/S0210-5691(05)74243-1).
6. García Urrea F, Luque Lezcano AO. MAMI registration report 1996–2010. *Cardiol J*. 2012;19:603–11, <http://dx.doi.org/10.5603/CJ.2012.0112>.
7. Dretzke J, Toff WD, Lip GYH, Raftery J, Fry-Smith A, Taylor RS. Dual chamber versus single chamber ventricular pacemakers for sick sinus syndrome and atrioventricular block. *Cochrane Database Syst Rev*. 2004:CD003710, <http://dx.doi.org/10.1002/14651858.CD003710.pub2>.
8. Ochagavía Calvo A, Baigorri González F. Selección del modo de estimulación del marcapasos. *Med Intensiva*. 2006;30:218–22, [http://dx.doi.org/10.1016/S0210-5691\(06\)74510-7](http://dx.doi.org/10.1016/S0210-5691(06)74510-7).
9. Nicolás Franco S, Rodríguez González FJ, Nicolás Boluda A, Sánchez Martos A. Importancia de la función ventricular en la elección del modo de electroestimulación cardíaca. *Med Intensiva*. 2015;39:172–8, <http://dx.doi.org/10.1016/j.medin.2014.09.002>.
10. Reglamento de acreditación y formación en estimulación cardíaca en medicina intensiva. SEMICYUC. [Accessed 16 September 2019]. Available from: https://semicyuc.org/wp-content/uploads/2018/12/formacion_estimulacion_cardiaca_7.pdf.

C. Salazar Ramírez^{a,*}, M. Nieto González^a, J.A. Fernández Lozano^b, J. Muñoz Bono^b, R. Gómez-López^c, M.C. Martín Delgado^d, Cardiological Intensive Care and Cardiopulmonary Resuscitation Working Group of the Spanish Society of Intensive and Critical Care Medicine and Coronary Units (SEMICYUC)

^a *Unidad de Estimulación Cardíaca de UCI, Servicio de Cuidados Críticos y Urgencias. Hospital Virgen de la Victoria de Málaga, Málaga, Spain*

^b *Unidad Coronaria, Servicio de Medicina Intensiva, Hospital Regional de Málaga, Málaga, Spain*

^c *Servicio de Medicina Intensiva, Hospital Quironsalud Miguel Domínguez, Pontevedra, Spain*

^d *Servicio Medicina Intensiva, Hospital Universitario de Torrejón, Torrejón de Ardoz (Madrid), Spain*

* Corresponding author.

E-mail addresses: cristinasweb@gmail.com (C. Salazar Ramírez), rociogmzlpz@gmail.com (R. Gómez-López).

0210-5691/ © 2020 Publicado por Elsevier España, S.L.U.

Innate cell response in severe SARS-CoV-2 infection in children: Expression analysis of CD64, CD18 and CD11a



Respuesta de celular innata en infección pediátrica grave por SARS-CoV-2: análisis de expresión de CD64, CD18 y CD11a

Dear Editor,

In January 2020, a new coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was described in Wuhan, China. The virus, which produces coronavirus disease 2019 (COVID-19), has been declared a global health emergency and pandemic by the World Health Organization. Spain is one of the more severely affected countries.¹

The immune response to SARS-CoV-2 infection appears to be a critical factor in the development and prognosis of COVID-19 patients.² In children, severe forms of the disease

like the pediatric multisystem inflammatory syndrome temporarily associated with SARS-CoV-2 appears to be related with some immune dysregulation.³ So, increase knowledge about the innate cellular immune response to SARS-CoV-2 is of great interest. To this, the study by flow cytometry (FC) may provide critical data and further understanding of this novel disease.³

In this paper, we study three molecules which are part of the innate cellular response to infection: CD64, CD18 and CD11a. The CD64 is a type I high-affinity receptor for the Fc fraction of the immunoglobulin G. It is located on monocytes, macrophages, dendritic cells, and neutrophils. The CD64 density on the cell surface is related to the stimulation received by inflammatory cytokines⁴. The CD18, also known as integrin beta-2, participates in leukocyte adhesion and signaling. The CD11a associates with CD18 to form the lymphocyte function-associated antigen 1, or LFA-1. This LFA-1 on leukocytes plays a central role in leukocyte cell-cell interactions and lymphocyte stimulation.

We study in this report three children with severe SARS-CoV-2 infection. Also, we compare them with a healthy control, a case of severe influenza infection and a case of Neisseria meningitidis sepsis. All cases

Table 1 Epidemiologic characteristics, clinical features, radiologic findings, and management of children admitted for pediatric critical care due to *Influenza B*, *Neisseria meningitidis* and SARS-CoV-2 infection.

| | Influenza B | Neisseria meningitidis | Case 1 | Case 2 | Case 3 |
|---|---|---|--|--|---|
| Age in years | 4 | 9 | 12 | 11 | 7 |
| Sex | Male | Male | Male | Male | Female |
| Referring department | Emergency department, 1 day of symptoms | Emergency department, 1 day of symptoms | Emergency department, 3 days of symptoms | Emergency department, 2 days of symptoms | Pediatric ward, 4 days of symptoms (one day of admission) |
| Previous diseases | No | No | No | No | No |
| Signs and symptoms prior to PICU admission | Tachipnea, hypoxemia, fever | Tachycardia, hypotension, fever | Fever, nausea, vomiting, diarrhea | Fever, nausea, diarrhea, adenopathy | Fever, abdominal pain |
| Cause of PICU admission | Respiratory instability | Hemodynamic instability | Hemodynamic instability | Hemodynamic instability | Hemodynamic instability |
| PRISM III | 0 | 3 | 4 | 4 | 7 |
| Total leukocytes/ μ L | 9640 | 5710 | 11,410 | 7880 | 3820 |
| Neutrophils/ μ L | 4360 | 3280 | 10,510 | 7150 | 3160 |
| Lymphocytes/ μ L | 4450 | 2110 | 320 | 430 | 410 |
| PCR mg/dl (0.01–1) | 8.2 | 13 | 15.88 | 16.67 | 11 |
| PCT ng/ml (0.1–0.5) | 0.33 | 3.75 | 4.28 | 10.29 | 1.78 |
| Ferritin ng/mL (7–140) | ND | ND | 888 | 1110 | 1349 |
| D-dimer mg/L (0–0.5) | ND | ND | 3.85 | 4.22 | 7.37 |
| IL-6 pg/ml (≤ 7) | ND | ND | 63.2 | 11 | 85 |
| Chest X-ray on PICU admission | Bilateral peribronchial thickening | No pathological findings | Bilateral pneumonia | No pathological findings | Bilateral pneumonia |
| Bilateral pneumonia developed while PICU treatment | No | No | Yes | No | Yes |
| Echocardiogram | Not done | Normal heart function | Normal heart function | Normal heart function | Normal heart function |
| Maximal respiratory support | BiPAP | Nassal cannula | HFNC | HFNC | HFNC |
| Inotropic support | No | No | No | No | Yes |
| Other support | No | No | No | No | No |
| Broad-spectrum antibiotics because of suspected bacterial coinfection | Yes | Yes | No | No | Yes |
| Azithromycin | No | No | Yes | Yes | Yes |
| Lopinavir/ritonavir | No | No | Yes | Yes | Yes |
| Remdesivir | No | No | No | No | No |
| Hydroxychloroquine | No | No | Yes | Yes | Yes |
| Steroids | No | No | Methylprednisolone (1 mg/kg/day) | Methylprednisolone (1 mg/kg/day) | Methylprednisolone (1 mg/kg/day) |
| Immunoglobulins | No | No | No | Yes | No |
| Tocilizumab | No | No | No | No | Yes |
| Heparin | No | No | Yes, prophylactic | Yes, prophylactic | Yes, prophylactic |
| Confirmed coinfection | No | No | No | No | No |
| Days of PICU admission | 5 | 7 | 5 | 6 | 9 |

PICU: pediatric intensive care unit; HFNC: high flow nasal cannula; BiPAP: Bilevel Positive Airway Pressure; pSOFA: Pediatric Sequential Organ Failure Assessment; PRISM III: Pediatric Risk of Mortality Score; ND: not done.




Figure 1 (A) CD64 staining on granulocytes, monocytes, and lymphocytes in peripheral blood samples obtained on pediatric critical care unit (PICU) admission. From left to right, we can observe the CD64 expression. CD64 is expressed on monocytes and neutrophils but not lymphocytes (internal negative control). The positive CD64 region is located to the right of the dotted line. As can be seen, neutrophils gated in the control case are crossed by this line. (B) Mean fluorescence intensity (MFI) values for CD64, CD11a, and CD18 are given for each case in the form of a bar chart. As can be seen in all cases, CD64 and CD11a expression is higher in SARS-CoV-2 cases. This observation is clear for CD64. The CD11a expression on CD8+ lymphocytes is also upregulated compared to previous data.

included had SARS-CoV-2 infection confirmed by real-time reverse transcriptase-polymerase chain reaction (RT-PCR) on nasopharyngeal swab samples. The cases trajectories, complementary tests, and therapy approaches are summarized in Table 1. The children were studied after informed consent was obtained. One 0.5 ml sample of peripheral blood was extracted on admission to the pediatric intensive care unit (PICU). The samples obtained were collected in sterile EDTA at room temperature or refrigerated at 4 °C, after which they were used for CD45+ cell-marker studies and analyzed by FC within 24 h. Cell surface expression of CD64, CD18, and CD11a was measured by BD FACS Canto II flow cytometer (Becton Dickinson, New York, USA). CD64 (clone 10.1), CD18 (clone CBR LFA-1/2), and CD11a (clone HI111) monoclonal antibodies were obtained from Biolegend® (San Diego, CA, USA). Expressions were measured in monocytes, neutrophils, and lymphocytes. Cell viability was confirmed by 7-AAD staining. At least 10,000 events were recorded for each sample. Flow-cytometric settings and samples were prepared according to manufacturer instructions. Neutrophils, monocytes and lymphocytes were identified on a dot-plot and gated (Fig. 1). The intensity of CD64, CD18, and CD11a surface expression was measured as mean fluorescence intensity in arbitrary units (MFI, Fig. 1B).⁵ The FC was performed on PICU admission in all cases. All patients received methylprednisolone prior to FC.

As results, we provide the description of CD64, CD18, and CD11a expression on neutrophils, monocytes and lymphocytes in children with severe SARS-CoV-2 disease. This expression appears to be higher compared to other infections and may point to an exacerbated cellular innate response in these children.³⁻⁶

The cytopathic effects of SARS-CoV-2 combined with the host immune response may play a major role in disease severity. A dysregulated immune response may result in inflammation and clinical worsening in patients with COVID-19. Elevated CD64 expression have been previously described in infectious and noninfectious diseases.⁷ Our

group carried out CD64 expression studies in acute bronchiolitis and severe viral and bacterial infections.⁵ As can be seen in Fig. 1 children with SARS-CoV-2 show levels of CD64 expression that are higher than in previous published reports of bacterial or viral infections or autoinflammatory diseases.⁵ Regarding the CD11a and CD18 complex or LFA-1, it is known that plays a key role in migration. Through these, leukocytes are mobilized from the bloodstream into tissues. One of the main findings in COVID-19 patients is the presence of lymphopenia.⁸ It can be seen in our cases. This may be linked to the migration of CD8+ lymphocytes to the infected tissues. As seen in Fig. 1, the CD11a upregulation in CD8+ is clear and could be linked to this process. The LFA-1 is also involved in the process of cytotoxic T cell-mediated killing as well as antibody-mediated killing by granulocytes and monocytes.⁹ The upregulation of both leukocyte populations is also observed in our cases (Fig. 1).

Immunomodulatory treatment seems to have a great role in COVID19. Their use should be based on a risk-benefit analysis. In SARS-CoV-2 infections the cytokine storm theory coupled with analytical data are used to justify these approaches.^{2,10} Our FC results introduce a new approach to analyzing the immune response to this new virus. We confirm the activation of the innate cellular response. Besides we observed that is different and maybe higher than in other infections. The description of this immune status using FC could individualize the diagnosis and optimize the therapies applied.

In summary, we describe the immunophenotype of three children with severe SARS-CoV-2 infection. We observed significant upregulation of CD64, CD18, and CD11a expression on leukocytes. Compare to previous papers and to other types of infection it appears to be higher. This could inform about immune dysregulation triggered by SARS-CoV-2. The use of FC may lead to a better understanding of this response and optimize the therapies applies. Prospective studies with a higher number of cases should be conducted to confirm this observation.

Financial disclosure

The authors have no financial relationships relevant to this article to disclose.

Conflict of interest

The authors have no conflicts of interest to disclose.

References

1. Tagarro A, Epalza C, Santos M, Sanz-Santaefemia FJ, Otheo E, Moraleda C, et al. Screening and Severity of Coronavirus Disease 2019 (COVID-19) in children in Madrid, Spain. *JAMA Pediatr.* 2020.
2. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response in patients with Coronavirus 2019 (COVID-19) in Wuhan, China. *Clin Infect Dis.* 2020;71:762–8.
3. Carter MJ, Fish M, Jennings A, Doores KJ, Wellman P, Seow J, et al. Peripheral immunophenotypes in children with multisystem inflammatory syndrome associated with SARS-CoV-2 infection. *Nat Med.* 2020.
4. Hu BQ, Yang Y, Zhao CJ, Liu DF, Kuang F, Zhang LJ, et al. Accuracy of neutrophil CD64 expression in diagnosing infection in patients with autoimmune diseases: a meta-analysis. *Clin Rheumatol.* 2019;38:1319–28.
5. García-Salido A, de Azagra-Garde AM, García-Teresa MA, Caro-Patón GL, Iglesias-Bouzas M, Nieto-Moro M, et al. Accuracy of CD64 expression on neutrophils and monocytes in bacterial infection diagnosis at pediatric intensive care admission. *Eur J Clin Microbiol Infect Dis.* 2019;38:1079–85.
6. Gupta R, Gant VA, Williams B, Enver T. Increased Complement Receptor-3 levels in monocytes and granulocytes distinguish COVID-19 patients with pneumonia from those with mild symptoms. *Int J Infect Dis.* 2020.
7. de Jong E, de Lange DW, Beishuizen A, van de Ven PM, Girbes AR, Huisman A. Neutrophil CD64 expression as a longitudinal biomarker for severe disease and acute infection in critically ill patients. *Int J Lab Hematol.* 2016;38:576–84.
8. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet (London, England).* 2020;395:1054–62.
9. Hyun YM, Choe YH, Park SA, Kim M. LFA-1 (CD11a/CD18) and Mac-1 (CD11b/CD18) distinctly regulate neutrophil extravasation through hotspots I and II. *Exp Mol Med.* 2019;51:1–13.
10. Zumla A, Hui DS, Azhar EI, Memish ZA, Maeurer M. Reducing mortality from 2019-nCoV: host-directed therapies should be an option. *Lancet (London, England).* 2020;395(10224):e35–6.

A. García-Salido^{a,*}, M.Á. García-Teresa^a, I. Leoz-Gordillo^a, A. Martínez de Azagra-Garde^a, M. Cabrero-Hernández^a, M. Ramirez-Orellana^b

^a *Pediatric Critical Care Unit, Hospital Infantil Universitario Niño Jesús, Madrid, Spain*

^b *Pediatric Oncohematology Unit, Flow Cytometry Laboratory, Hospital Infantil Universitario Niño Jesús, Madrid, Spain*

* Corresponding author.

E-mail address: citopensis@yahoo.es (A. García-Salido).

0210-5691 / © 2020 Elsevier España, S.L.U. y SEMICYUC. All rights reserved.

Restrictive or liberal transfusion for cardiac surgery: Spanish results of a randomized multicenter international parallel open-label clinical trial



Transfusión Restrictiva o liberal en cirugía cardíaca: Resultados españoles de un ensayo clínico aleatorizado, multicéntrico, internacional, paralelo y abierto

Dear Editor,

In cardiac surgery, red blood cell (RBC) transfusion is very frequent. Although transfusion is useful to treat anemia and avoid its complications, it represents a potential risk of acute kidney damage at 72 h after surgery, prolonged mechanical ventilation, need for hemodynamic support, increase-hospital mortality, as well as longer hospital stays.¹ Finding the optimal threshold of hemoglobin for indicating the transfusion with maximal benefit and minimal risk is an aim of the clinical practice. However, a survey in 34 Spanish centers performed in 2007 showed that 70% centers did not

have homeostasis protocols and 75% of patients undergoing cardiac surgery were transfused.²

Because of the wide variability in transfusion practices and high rates of transfusion in cardiac surgery in Spain, we participated in the Transfusion Requirements in Cardiac Surgery (TRICS) III trial. This is a randomized, multicentre, international, controlled, open-label clinical trial to assess whether a restrictive transfusion strategy, in which lower hemoglobin concentrations for RBC transfusion, applied throughout the perioperative period, would be non-inferior, in terms of major morbidities and mortality, to a liberal approach among 5243 patients undergoing cardiac surgery.^{3,4} This study was funded by national peer-review organizations from Australia, Canada, Spain (ISCIII and European Social Fund, CP15/00116) and New Zealand.

We present the results of the Spanish included patients followed up to 6 months after surgery.

Ethics approval was provided by each institutional review boards. All patients consented to participate in the clinical trial. An independent data and safety monitoring board provided trial oversight.

The inclusion criteria were patients undergoing cardiac surgery with cardiopulmonary bypass at moderate to high predicted risk for death, as defined by the European System for Cardiac Operative Risk Evaluation